Alrgn Bio develops patented non-GMO food processing technologies to reduce allergens in peanuts and tree nuts. Its first solution to be commercialized, Safer Peanut™, is a revolutionary post-harvest enzymatic process that safely deactivates dangerous allergens in peanuts. Independent testing shows the deactivation of up to 99%+ of the key allergenic proteins. Safer Peanuts look, crunch, taste, and process like non-treated peanuts. Food companies currently sell an estimated $20+ billion of peanut based foods in the US each year. By licensing our Safer Peanut process, these companies can extend current product lines and/or develop new categories of allergen reduced foods (e.g. peanut butter, peanut flour, airline snacks, candy, cookies, breakfast cereals, energy bars, protein drinks, etc.). These new reduced allergen product lines will create higher profit margins and deliver larger market share, while promoting safer environments (schools, airplanes, restaurants, stadiums, etc.) for those with peanut allergies.
Peanut-based foods have been banned in many public spaces (schools, airplanes, etc.). We believe that a new food category of Safer Peanutbased products will allow food companies to differentiate their products and regain access to these markets. Safer Peanuts will also provide restaurants and other venues that currently serve unsafe peanuts an inexpensive alternative that will mitigate legal liability.
The Senior Research Officer position is currently available at Alrgn Bio. The primary purpose of this position is to continue research to optimize enzyme-based treatment processes to reduce allergens in peanuts, tree nuts and other food products. Alrgn Bio, Inc. develops and commercializes patented food processing technologies to reduce allergens in foods. Its first commercialized solution, Safer Peanut, is a revolutionary post-harvest enzymatic process that safely deactivates dangerous allergens in peanuts.
This role will be fulfilled in the research triangle of Greensboro, Raleigh, and Durham.